EXACT Sciences (EXAS) - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US30063P1057
Exact Sciences Corporation is a company that offers cancer screening and diagnostic test products globally, in addition to the United States. The company's flagship product, Cologuard, is a stool-based DNA screening test used to detect biomarkers linked to colorectal cancer and pre-cancer. Furthermore, Exact Sciences provides various other tests such as the Oncotype DX Breast and Colon Recurrence Score Tests, as well as the OncoExTra Test for tumor profiling in patients with advanced cancer.
Moreover, Exact Sciences Corporation also provides Covid-19 testing services. The company is continuously working on improving the performance of the Cologuard test and developing new tests based on blood and other bodily fluids. Additionally, Exact Sciences holds license agreements with MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, the company is headquartered in Madison, Wisconsin.
For more information, visit their website: https://www.exactsciences.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
EXAS Stock Overview
| Market Cap in USD | 12,537m |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| GiC SubIndustry | Biotechnology |
| TER | 0.00% |
| IPO / Inception | 2001-02-01 |
EXAS Stock Ratings
| Growth 5y | -3.13 |
| Fundamental | -1.67 |
| Dividend | - |
| Rel. Performance vs Sector | -0.92 |
| Analysts | 4.70/5 |
| Fair Price Momentum | 52.93 USD |
| Fair Price DCF | 4.92 USD |
EXAS Dividends
| Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
EXAS Growth Ratios
| Growth 12m | -9.61% |
| Growth Correlation 12m | -45% |
| Growth Correlation 3m | 13% |
| CAGR 5y | -7.61% |
| Sharpe Ratio 12m | -0.33 |
| Alpha vs SP500 12m | -38.40 |
| Beta vs SP500 5y weekly | 1.42 |
| ValueRay RSI | 17.87 |
| Volatility GJR Garch 1y | 68.69% |
| Price / SMA 50 | -3.62% |
| Price / SMA 200 | -14.04% |
| Current Volume | 2168.8k |
| Average Volume 20d | 3197.4k |
External Links for EXAS Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of April 20, 2024, the stock is trading at USD 60.96 with a total of 2,168,842 shares traded.
Over the past week, the price has changed by -14.55%, over one month by -1.52%, over three months by -7.43% and over the past year by -11.24%.
According to ValueRays Forecast Model, EXAS EXACT Sciences will be worth about 58.9 in April 2025. The stock is currently trading at 60.96. This means that the stock has a potential downside of -3.33%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 89.9 | 47.5% |
| Analysts Target Price | 106.4 | 74.5% |
| ValueRay Target Price | 58.9 | -3.33% |